Myelogenous Leukemia in Relapse
1 clinical trials · Condition
◉ Watch Myelogenous Leukemia in Relapse
| Record | Firm | Date |
|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML (NCT07157514) | Actinium Pharmaceuticals | 2026-01-01 |
Track Myelogenous Leukemia in Relapse automatically
Every clearance here is in the API, with alerts when new ones post.